135 related articles for article (PubMed ID: 37819139)
21. The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.
Vickers AJ; Eastham JA; Scardino PT; Lilja H
Urology; 2016 May; 91():12-8. PubMed ID: 26850815
[TBL] [Abstract][Full Text] [Related]
22. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
23. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
Heijnsdijk EAM; Gulati R; Tsodikov A; Lange JM; Mariotto AB; Vickers AJ; Carlsson SV; Etzioni R
J Natl Cancer Inst; 2020 Oct; 112(10):1013-1020. PubMed ID: 32067047
[TBL] [Abstract][Full Text] [Related]
24. Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
Paschen U; Sturtz S; Fleer D; Lampert U; Skoetz N; Dahm P
BJU Int; 2022 Mar; 129(3):280-289. PubMed ID: 33961337
[TBL] [Abstract][Full Text] [Related]
25. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
26. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
Nyame YA; Gulati R; Heijnsdijk EAM; Tsodikov A; Mariotto AB; Gore JL; Etzioni R
J Natl Cancer Inst; 2021 Oct; 113(10):1336-1342. PubMed ID: 33963850
[TBL] [Abstract][Full Text] [Related]
28. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
29. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
30. Predicting 7-year mortality for use with evidence-based guidelines for Prostate-Specific Antigen (PSA) testing: findings from a large prospective study of 123 697 Australian men.
Joshy G; Banks E; Lowe A; Wolfe R; Tickle L; Armstrong B; Clements M
BMJ Open; 2018 Dec; 8(12):e022613. PubMed ID: 30552254
[TBL] [Abstract][Full Text] [Related]
31. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
32. A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis.
Rychetnik L; Doust J; Thomas R; Gardiner R; Mackenzie G; Glasziou P
BMJ Open; 2014 Apr; 4(4):e004682. PubMed ID: 24785399
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
34. Spatial patterns of prostate-specific antigen testing in asymptomatic men across Australia: a population-based cohort study, 2017-2018.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Public Health; 2023 Apr; 217():173-180. PubMed ID: 36898290
[TBL] [Abstract][Full Text] [Related]
35. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
36. Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing.
Jackson SD; de la Rue MR; Greenslade TP; John AM; Wahid S; Martin RM; Williams NJ; Turner EL
J Med Screen; 2022 Dec; 29(4):268-271. PubMed ID: 36062629
[TBL] [Abstract][Full Text] [Related]
37. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia.
Pashayan N; Powles J; Brown C; Duffy SW
Br J Cancer; 2006 Aug; 95(3):401-5. PubMed ID: 16832417
[TBL] [Abstract][Full Text] [Related]
38. Expected population impacts of discontinued prostate-specific antigen screening.
Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
[TBL] [Abstract][Full Text] [Related]
39. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
